SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Citigroup initiated coverage on Ascendis Pharma A/S (ASND) with a Buy…

Ascendis Pharma A/S · ANALYST-UPGRADE filed

At the news

BULLISHIMPACT 3/10

ANALYST-UPGRADE filed

Citigroup initiated coverage on Ascendis Pharma A/S (ASND) with a Buy rating and a $355 price target, representing 44.6% upside from the current price of $245.49. The new PT tops the Street, surpassing the prior high of $341.98 and sitting 20% above the consensus mean of $295.96. Citigroup's track record shows 55% accuracy on 4,355 calls with a 4.9% average return, placing it in the middle tier among firms covering ASND. Consensus is overwhelmingly bullish, 23 of 24 analysts rate the stock Buy (95.8%), with just one Hold and no Sells. EPS estimates have surged over the past week: current-year EPS is now $10.21 versus $2.82 seven days ago, reflecting strong upward revisions. Institutional buyers are piling in, Two Sigma, Morgan Stanley, and UBS have all significantly added or doubled positions, while short interest sits at 91.5%, a potential squeeze catalyst. However, CEO Flemming Steen Jensen sold $4.64M in shares on May 11, a bearish insider signal that partially offsets the bullish initiation. Overall, the call aligns with an already bullish consensus and is reinforced by positive earnings momentum and heavy institutional accumulation.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access